Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
ImmuCell Corporationâs (Nasdaq: ICCC) purpose is to create scientifically-proven...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...
Myriad Genetics, Inc., is a leading precision m...
Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...
Achieve is a specialty pharmaceutical company c...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
Join the National Investor Network and get the latest information with your interests in mind.